多模式机械支在耐火性心脏性休克中使用,因布罗过量服用
Kevin Bodker1, Abdulghani Mounir2, Nathan Marzlin2
1Cardiology, Medical University of South Carolina, Charleston, USA.
Cureus
|October 16, 2023
概括
大量的布普罗过量服用可能会导致心脏性休克. 这个案例展示了机械循环支持 (Impella CP) 和体外治疗 (分子吸附剂循环系统) 如何成功治疗过量服用的严重心脏功能障碍和心律失常.
科学领域:
- 心脏病学 心脏病学
- 毒理学 毒理学 毒理学
- 关键护理医学 关键护理医学
背景情况:
- 大规模的布普罗过量服用与严重的心脏性休克有关.
- 静脉动脉风暴可以复杂化布洛普的毒性.
- 左心室低运动是严重过量服用的关键发现.
研究的目的:
- 报告一个巨大的布洛普过量与心脏性休克的病例.
- 为了说明布洛普诱导的心脏性休克和心室动脉冲击风暴的成功管理.
- 突出结合机械循环支持和体外治疗的实用性.
主要方法:
- 一名48岁的女性出现了大量的布普罗过量.
- 胸外心声扫描显示了严重的左心室低运动 (射出分数9%).
- 管理包括Impella CP设备,分子吸附剂循环系统和体外膜氧化.
主要成果:
- 患者经历了恶化的心脏性休克和心室动脉冲击风暴.
- 干预后,鼻节律在24小时内恢复.
- 重复回声心脏图显示左心室功能得到改善,临床状况有了深刻的改善.
结论:
- 联合使用Impella CP,分子吸附剂循环系统和ECMO可以在大量布洛过量时挽救生命.
- 这种治疗方法有效地支持关键过量场景中的心脏恢复.
- 早期和积极的干预对于管理布洛普诱导的心脏病性休克至关重要.
相关概念视频
Cardiopulmonary Resuscitation IV: Pharmacological Management
12
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
12
Heart Failure V: Medical Management
10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10
Heart Failure Drugs: Inotropic Agents
598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
441
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
441


